Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07223723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)

StatusActive, Not Recruiting
PhasePhase 4
SponsorBiogen
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Primary and study completion moved earlier from Dec 16, 2027 to May 26, 2027 · Site details revisedv3 Show 2 more changesShow less
    • Primary and study completion moved earlier from Dec 16, 2027 to May 26, 2027
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2, 2025 to Dec 11, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2, 2025 to Dec 11, 2025
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Biogen
92 trials monitored
See 7 trials at risk
ALS
387 trials monitored
See 18 trials at risk
In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for people with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in people who have a mutation in the superoxide dismutase 1 gene, also known as SOD-1. This is known as a "postmarketing" study. In this kind of the study, the goal is to learn more about how a drug works after it has been approved for use in the general public. Tofersen was approved in China in September 2024. The main goal of this study is to collect long-term safety information in Chinese participants with SOD-1 ALS. The main question researchers want to answer in this study is: • How many participants have adverse events (AEs) and serious adverse events (SAEs)? An AE is a health problem that may or may not be caused by a drug during the study. An AE is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care. Researchers will also learn more about : * How the body processes tofersen. * How much tofersen is found in the cerebrospinal fluid (CSF), or the fluid that surrounds the brain and the spinal cord. This study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks. * After joining the study, participants will receive the first 3 doses of 100 milligrams (mg) of tofersen about 14 days apart. This will be given through an intrathecal (IT) injection. This means it will be given into the fluid surrounding the spine. * After that, participants will receive 10 more doses every 28 days through IT injections. Participants will have up to 13 total doses of tofersen in this study. * Participants will have up to 15 visits to their study research center. Each participant will be in the study for up to 52 weeks (1 year).
Trial Details
NCT Number NCT07223723
Lead Sponsor Biogen
Conditions Amyotrophic Lateral Sclerosis
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov